Blog
Provides refreshingly forthright, objective comment on small cap companies. Informed opinion, based on first-hand research, but pulls no punches in exposing management weaknesses.
IS Pharma plc – placing at a premium gives confidence and we get a dividend as well
Posted 06/10/10
The speciality pharmaceutical company has announced that it has raised £3.6m at 77p per share with Abingworth LLP, the strategic healthcare investor. The placing price surprisingly (at least in this market) represents a 9% premium to the closing price of 70.5p the day before the announcement.
Continue reading... | Permalink | Filed under IS Pharma
IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme
Posted 02/06/10
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology saw revenue up 17% to £14.2m (2009: £12.2m).
Continue reading... | Permalink | Filed under IS Pharma
IS Pharma (LON:ISPH)
Posted 30/04/10
The specialist pharmaceuticals company launches more brands internationally
Continue reading... | Permalink | Filed under IS Pharma
IS Pharma (LON:ISPH) snaps up the rights to Episil
Posted 04/03/10
The international speciality pharmaceutical company is on the acquisition trail again!
Continue reading... | Permalink | Filed under IS Pharma
IS Pharma : Variquel® approval and management continues to shine
Posted 23/11/09
IS Pharma (LSE: ISPH), the international speciality pharmaceutical company, and a real star EIS qualifying issue from 2007 continues to deliver.
Continue reading... | Permalink | Filed under IS Pharma
